Targeted therapy of acute myeloid leukemia in 2012

Towards individualized therapy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Advances in molecular diagnostics in acute myeloid leukemia (AML) have translated into significant advances in our understanding of disease prognosis and biology, and the identification of new targets for therapy. The best described of these are mutations in Fms-like tyrosine kinase 3, nucleophosmin 1, and CCAAT enhancer-binding protein-alpha in those with cytogenetically AML, which allow more accurate risk stratification and help better 'target' patients who may benefit from allogeneic transplantation (specifically those with activating FLT3 mutation). Among the new targets identified for clinical trials are FLT3 mutation (a target for tyrosine kinase inhibitors), CD33 expression (a target of monoclonal antibodies and immunotoxins), aberrant methylation (target of hypomethylating agents), and overexpression of the chemokine receptor CXCR4 (a target for inhibition by small molecule or monoclonal antibody). We are advancing towards an era of personalized medicine in AML, and can now better identify specific patients who may benefit from specific therapies with less toxicity.

Original languageEnglish (US)
JournalHematology
Volume17
Issue numberSUPPL. 1
DOIs
StatePublished - Apr 2012

Fingerprint

Acute Myeloid Leukemia
Mutation
fms-Like Tyrosine Kinase 3
Monoclonal Antibodies
CCAAT-Enhancer-Binding Protein-alpha
Immunotoxins
Precision Medicine
Molecular Pathology
Chemokine Receptors
Homologous Transplantation
Protein-Tyrosine Kinases
Methylation
Therapeutics
Clinical Trials

Keywords

  • Acute myeloid leukemia
  • Personalized
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Targeted therapy of acute myeloid leukemia in 2012 : Towards individualized therapy. / Foran, James M.

In: Hematology, Vol. 17, No. SUPPL. 1, 04.2012.

Research output: Contribution to journalArticle

@article{2926815f99e3432e88fe0b619c453d45,
title = "Targeted therapy of acute myeloid leukemia in 2012: Towards individualized therapy",
abstract = "Advances in molecular diagnostics in acute myeloid leukemia (AML) have translated into significant advances in our understanding of disease prognosis and biology, and the identification of new targets for therapy. The best described of these are mutations in Fms-like tyrosine kinase 3, nucleophosmin 1, and CCAAT enhancer-binding protein-alpha in those with cytogenetically AML, which allow more accurate risk stratification and help better 'target' patients who may benefit from allogeneic transplantation (specifically those with activating FLT3 mutation). Among the new targets identified for clinical trials are FLT3 mutation (a target for tyrosine kinase inhibitors), CD33 expression (a target of monoclonal antibodies and immunotoxins), aberrant methylation (target of hypomethylating agents), and overexpression of the chemokine receptor CXCR4 (a target for inhibition by small molecule or monoclonal antibody). We are advancing towards an era of personalized medicine in AML, and can now better identify specific patients who may benefit from specific therapies with less toxicity.",
keywords = "Acute myeloid leukemia, Personalized, Targeted therapy",
author = "Foran, {James M}",
year = "2012",
month = "4",
doi = "10.1179/102453312X13336169156456",
language = "English (US)",
volume = "17",
journal = "Hematology",
issn = "1024-5340",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Targeted therapy of acute myeloid leukemia in 2012

T2 - Towards individualized therapy

AU - Foran, James M

PY - 2012/4

Y1 - 2012/4

N2 - Advances in molecular diagnostics in acute myeloid leukemia (AML) have translated into significant advances in our understanding of disease prognosis and biology, and the identification of new targets for therapy. The best described of these are mutations in Fms-like tyrosine kinase 3, nucleophosmin 1, and CCAAT enhancer-binding protein-alpha in those with cytogenetically AML, which allow more accurate risk stratification and help better 'target' patients who may benefit from allogeneic transplantation (specifically those with activating FLT3 mutation). Among the new targets identified for clinical trials are FLT3 mutation (a target for tyrosine kinase inhibitors), CD33 expression (a target of monoclonal antibodies and immunotoxins), aberrant methylation (target of hypomethylating agents), and overexpression of the chemokine receptor CXCR4 (a target for inhibition by small molecule or monoclonal antibody). We are advancing towards an era of personalized medicine in AML, and can now better identify specific patients who may benefit from specific therapies with less toxicity.

AB - Advances in molecular diagnostics in acute myeloid leukemia (AML) have translated into significant advances in our understanding of disease prognosis and biology, and the identification of new targets for therapy. The best described of these are mutations in Fms-like tyrosine kinase 3, nucleophosmin 1, and CCAAT enhancer-binding protein-alpha in those with cytogenetically AML, which allow more accurate risk stratification and help better 'target' patients who may benefit from allogeneic transplantation (specifically those with activating FLT3 mutation). Among the new targets identified for clinical trials are FLT3 mutation (a target for tyrosine kinase inhibitors), CD33 expression (a target of monoclonal antibodies and immunotoxins), aberrant methylation (target of hypomethylating agents), and overexpression of the chemokine receptor CXCR4 (a target for inhibition by small molecule or monoclonal antibody). We are advancing towards an era of personalized medicine in AML, and can now better identify specific patients who may benefit from specific therapies with less toxicity.

KW - Acute myeloid leukemia

KW - Personalized

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84859754212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859754212&partnerID=8YFLogxK

U2 - 10.1179/102453312X13336169156456

DO - 10.1179/102453312X13336169156456

M3 - Article

VL - 17

JO - Hematology

JF - Hematology

SN - 1024-5340

IS - SUPPL. 1

ER -